Close
Close

A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

Access Programs

Disease Information

Descriptive Information
Brief Title † A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
Official Title † Gastroenteropancreatic and Unknown Primary Neuroendocrine Registry A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
Brief Summary The purpose of this study is to establish a neuroendocrine tumor registry. A registry is a collection of information. To create this registry, the investigators would like to get information, blood and tumor samples from people with neuroendocrine tumors. By collecting this information and material, the investigators are hoping to learn more about the genetic causes of neuroendocrine tumors. All of this will help us to better understand neuroendocrine cancer, so the investigators can find better ways to treat and diagnose this disease. DNA will be taken from the blood samples and will be used in future studies. This will be an important resource from which the investigators can study genes that may be related to a higher risk of neuroendocrine tumors. The information collected will include medical information, family history of cancer and your answers to questions about how the cancer affects quality of life.
Detailed Description
Study Phase N/A
Study Type † Observational
Study Design † Observational Model: Cohort, Time Perspective: Prospective
Primary Outcome Measure † To develop a tissue, serum, plasma and DNA bank from individuals with NET. This bank will be combined with epidemiologic and clinical information to create a NET database.
Secondary Outcome Measure †
Condition † Gastric Cancer Pancreatic Cancer
Intervention † Otherquestionnaire, Blood specimens
Study Arms / Comparison Groups 1 This registry will be open to all patients with GEPNET or NET of unknown primary.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Other
Estimated Enrollment † 300
Start Date † August 2008
Completion Date August 2016
Primary Completion Date August 2016
Eligibility Criteria † Inclusion Criteria: - Diagnosis of gastroenteropancreatic neuroendocrine tumors or neuroendocrine tumors of unknown primary - Willing to donate blood samples - >= 18years old - Patients may have received prior hormonal therapy, cytotoxic therapy, irradiation, immunotherapy or surgical therapy Exclusion Criteria: - Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent
Gender Both
Ages 18 Years - N/A
Accepts Healthy Volunteers No
Contacts ††
Location Countries † United States
Administrative Information
NCT ID † NCT00745381
Organization ID 08-105
Secondary IDs ††
Responsible Party Sponsor
Study Sponsor † Memorial Sloan Kettering Cancer Center
Collaborators ††
Investigators † Principal Investigator: Diane Reidy-Lagunes, MD, Memorial Sloan Kettering Cancer Center
Information Provided By
Verification Date August 2015
First Received Date † September 2, 2008
Last Updated Date August 14, 2015
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
Free Newsletter